Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Genetics

Pharmaceutical

Clinical Trials

Q1 2024 Financial Results

More Like This

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)